collection
Collections Top Papers for 2018 - Endocrin...

Top Papers for 2018 - Endocrinology, Metabolism

Top Papers for 2018 - Endocrinology, Metabolism

https://read.qxmd.com/read/29547046/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-2018-position-statement-on-integration-of-insulin-pumps-and-continuous-glucose-monitoring-in-patients-with-diabetes-mellitus
#41
JOURNAL ARTICLE
George Grunberger, Yehuda Handelsman, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, Richard A Haas, Victor L Roberts, Guillermo E Umpierrez
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there are no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician...
March 2018: Endocrine Practice
https://read.qxmd.com/read/29594056/2018-european-thyroid-association-eta-guidelines-for-the-management-of-amiodarone-associated-thyroid-dysfunction
#42
JOURNAL ARTICLE
Luigi Bartalena, Fausto Bogazzi, Luca Chiovato, Alicja Hubalewska-Dydejczyk, Thera P Links, Mark Vanderpump
Treatment with amiodarone is associated with changes in thyroid function tests, but also with thyroid dysfunction (amiodarone-induced hypothyroidism, AIH, and amiodarone-induced thyrotoxicosis, AIT). Both AIH and AIT may develop in apparently normal thyroid glands or in the presence of underlying thyroid abnormalities. AIH does not require amiodarone withdrawal, and is treated with levothyroxine replacement if overt, whereas subclinical forms may be followed without treatment. Two main types of AIT are recognized: type 1 AIT (AIT 1), a form of iodine-induced hyperthyroidism occurring in nodular goitres or latent Graves disease, and type 2 AIT (AIT 2), resulting from destructive thyroiditis in a normal thyroid gland...
March 2018: European Thyroid Journal
https://read.qxmd.com/read/30373146/the-pathophysiology-of-gestational-diabetes-mellitus
#43
REVIEW
Jasmine F Plows, Joanna L Stanley, Philip N Baker, Clare M Reynolds, Mark H Vickers
Gestational diabetes mellitus (GDM) is a serious pregnancy complication, in which women without previously diagnosed diabetes develop chronic hyperglycemia during gestation. In most cases, this hyperglycemia is the result of impaired glucose tolerance due to pancreatic β-cell dysfunction on a background of chronic insulin resistance. Risk factors for GDM include overweight and obesity, advanced maternal age, and a family history or any form of diabetes. Consequences of GDM include increased risk of maternal cardiovascular disease and type 2 diabetes and macrosomia and birth complications in the infant...
October 26, 2018: International Journal of Molecular Sciences
https://read.qxmd.com/read/29848235/american-thyroid-association-statement-on-postoperative-hypoparathyroidism-diagnosis-prevention-and-management-in-adults
#44
JOURNAL ARTICLE
Lisa A Orloff, Sam M Wiseman, Victor J Bernet, Thomas J Fahey, Ashok R Shaha, Maisie L Shindo, Samuel K Snyder, Brendan C Stack, John B Sunwoo, Marilene B Wang
BACKGROUND: Hypoparathyroidism (hypoPT) is the most common complication following bilateral thyroid operations. Thyroid surgeons must employ strategies for minimizing and preventing post-thyroidectomy hypoPT. The objective of this American Thyroid Association Surgical Affairs Committee Statement is to provide an overview of its diagnosis, prevention, and treatment. SUMMARY: HypoPT occurs when a low intact parathyroid hormone (PTH) level is accompanied by hypocalcemia...
July 2018: Thyroid: Official Journal of the American Thyroid Association
https://read.qxmd.com/read/30122971/current-treatment-options-for-acanthosis-nigricans
#45
REVIEW
Nupur U Patel, Catherine Roach, Hossein Alinia, William W Huang, Steven R Feldman
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. While the goal of therapy is to treat the primary cause, cosmetic resolution of AN lesions can be important for patients and their quality of life...
2018: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/29925743/tsh-ratio-as-a-novel-diagnostic-method-for-cushing-s-syndrome
#46
JOURNAL ARTICLE
Daisuke Tamada, Tetsuhiro Kitamura, Mitsuyoshi Takahara, Toshihisa Tanaka, Masatoshi Takeda, Michio Otsuki, Iichiro Shimomura
Circadian variations impact thyrotropin (TSH) secretion; in Cushing's syndrome (CS) patients, the nocturnal serum TSH surge is abolished. The aim of this prospective study is to examine whether serum TSH surge may be a useful diagnostic method for CS. This prospective study recruited 136 inpatients for differential diagnosis of CS or subclinical CS (SCS), and 21 inpatients with depression at Osaka University Hospital. Serum TSH surge was assessed by the midnight-to-morning serum TSH ratio (2300-2400 h to 0800-0900 h)...
August 27, 2018: Endocrine Journal
https://read.qxmd.com/read/30374425/2018-european-thyroid-association-eta-guidelines-on-the-diagnosis-and-management-of-central-hypothyroidism
#47
JOURNAL ARTICLE
Luca Persani, Georg Brabant, Mehul Dattani, Marco Bonomi, Ulla Feldt-Rasmussen, Eric Fliers, Annette Gruters, Dominique Maiter, Nadia Schoenmakers, A S Paul van Trotsenburg
OBJECTIVES: Central hypothyroidism (CeH) is a rare form of hypothyroidism characterized by insufficient thyroid stimulation due to disturbed pituitary and/or hypothalamic functioning. Due to its origin and the whole clinical context, CeH represents a challenging condition in clinical practice as it is characterized by suboptimal accuracy of clinical and biochemical parameters for diagnosis and management. Since no expert consensus or guidance for this condition is currently available, a task force of experts received the commitment from the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence...
October 2018: European Thyroid Journal
https://read.qxmd.com/read/30269342/diagnosis-and-management-of-central-diabetes-insipidus-in-adults
#48
REVIEW
Aoife Garrahy, Carla Moran, Christopher J Thompson
Central diabetes insipidus (CDI) is characterized by hypotonic polyuria due to impairment of AVP secretion from the posterior pituitary. In clinical practice, it needs to be distinguished from renal resistance to the antidiuretic effects of AVP (nephrogenic DI), and abnormalities of thirst appreciation (primary polydipsia). As nephrogenic diabetes insipidus is rare in adults, unless they are treated with lithium salts, the practical challenge is how to differentiate between CDI and clinical disorders of excess thirst...
January 2019: Clinical Endocrinology
https://read.qxmd.com/read/29404568/vitamin-and-mineral-supplements-what-clinicians-need-to-know
#49
JOURNAL ARTICLE
JoAnn E Manson, Shari S Bassuk
No abstract text is available yet for this article.
March 6, 2018: JAMA
https://read.qxmd.com/read/29498920/update-on-the-clinicopathology-of-pituitary-adenomas
#50
REVIEW
Chung Thong Lim, Márta Korbonits
OBJECTIVE: Pituitary adenomas are the third most common central nervous system tumors and arise from the anterior pituitary within the pituitary fossa. METHODS: Literature review and discussion. RESULTS: The signs and symptoms of patients with pituitary adenomas vary from 'mass effects' caused by a large adenoma to features secondary to excess pituitary hormones produced by the functioning pituitary adenoma. Detailed histopathologic assessment, based on novel classifications and the latest World Health Organization guidelines, helps to categorize pituitary adenomas into different subtypes and identify features that, in some cases, help to predict their behavior...
May 2018: Endocrine Practice
https://read.qxmd.com/read/30477754/primary-hyperparathyroidism
#51
REVIEW
Barbara C Silva, Natalie E Cusano, John P Bilezikian
Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal women with hypercalcemia and parathyroid hormone (PTH) levels that are either frankly elevated or inappropriately normal. The clinical presentation of PHPT includes three phenotypes: target organ involvement of the renal and skeletal systems; mild asymptomatic hypercalcemia; and more recently, high PTH levels in the context of persistently normal albumin-corrected and ionized serum calcium values...
September 28, 2018: Best Practice & Research. Clinical Endocrinology & Metabolism
https://read.qxmd.com/read/30324792/diagnosis-of-endocrine-disease-congenital-hypothyroidism-update-and-perspectives
#52
REVIEW
C Peters, A S P van Trotsenburg, N Schoenmakers
Congenital hypothyroidism (CH) may be primary, due to a defect affecting the thyroid gland itself, or central, due to impaired thyroid-stimulating hormone (TSH)-mediated stimulation of the thyroid gland as a result of hypothalamic or pituitary pathology. Primary CH is the most common neonatal endocrine disorder, traditionally subdivided into thyroid dysgenesis (TD), referring to a spectrum of thyroid developmental abnormalities, and dyshormonogenesis, where a defective molecular pathway for thyroid hormonogenesis results in failure of hormone production by a structurally intact gland...
December 1, 2018: European Journal of Endocrinology
https://read.qxmd.com/read/29438552/estrogen-replacement-in-turner-syndrome-literature-review-and-practical-considerations
#53
REVIEW
Karen O Klein, Robert L Rosenfield, Richard J Santen, Aneta M Gawlik, Philippe F Backeljauw, Claus H Gravholt, Theo C J Sas, Nelly Mauras
CONTEXT: Most girls with Turner syndrome (TS) have hypergonadotropic hypogonadism and need hormonal replacement for induction of puberty and then for maintaining secondary sex characteristics, attaining peak bone mass, and uterine growth. The optimal estrogen replacement regimen is still being studied. EVIDENCE ACQUISITION: We conducted a systematic search of PubMed for studies related to TS and puberty. EVIDENCE SYNTHESIS: The goals of replacement are to mimic normal timing and progression of physical and social development while minimizing risks...
May 1, 2018: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/29684108/pituitary-diseases-and-bone
#54
REVIEW
Gherardo Mazziotti, Stefano Frara, Andrea Giustina
Neuroendocrinology of bone is a new area of research based on the evidence that pituitary hormones may directly modulate bone remodeling and metabolism. Skeletal fragility associated with high risk of fractures is a common complication of several pituitary diseases such as hypopituitarism, Cushing disease, acromegaly, and hyperprolactinemia. As in other forms of secondary osteoporosis, pituitary diseases generally affect bone quality more than bone quantity, and fractures may occur even in the presence of normal or low-normal bone mineral density as measured by dual-energy X-ray absorptiometry, making difficult the prediction of fractures in these clinical settings...
August 1, 2018: Endocrine Reviews
https://read.qxmd.com/read/29619209/contemporary-approaches-to-the-management-of-polycystic-ovary-syndrome
#55
REVIEW
Renato Pasquali
Polycystic ovary syndrome (PCOS) is a common disorder in women in their reproductive years and is characterized by androgen excess, ovulatory dysfunction, and polycystic ovarian morphology. It is also associated with several metabolic abnormalities, particularly insulin resistance and obesity, which play an important role in the pathophysiology of PCOS and, in particular, negatively influence ovarian function and fertility. This review article summarizes the available treatment for women with PCOS. Specifically, current and potentially new therapies are discussed...
April 2018: Therapeutic Advances in Endocrinology and Metabolism
https://read.qxmd.com/read/29368965/consensus-statement-by-the-american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-on-the-comprehensive-type-2-diabetes-management-algorithm-2018-executive-summary
#56
JOURNAL ARTICLE
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca, Jeffrey R Garber, W Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B Hirsch, Paul S Jellinger, Janet B McGill, Jeffrey I Mechanick, Paul D Rosenblit, Guillermo E Umpierrez
No abstract text is available yet for this article.
January 2018: Endocrine Practice
https://read.qxmd.com/read/30425094/evaluation-and-management-of-youth-onset-type-2-diabetes-a-position-statement-by-the-american-diabetes-association
#57
REVIEW
Silva Arslanian, Fida Bacha, Margaret Grey, Marsha D Marcus, Neil H White, Philip Zeitler
No abstract text is available yet for this article.
December 2018: Diabetes Care
https://read.qxmd.com/read/29677303/association-between-use-of-sodium-glucose-cotransporter-2-inhibitors-glucagon-like-peptide-1-agonists-and-dipeptidyl-peptidase-4-inhibitors-with-all-cause-mortality-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#58
REVIEW
Sean L Zheng, Alistair J Roddick, Rochan Aghar-Jaffar, Matthew J Shun-Shin, Darrel Francis, Nick Oliver, Karim Meeran
IMPORTANCE: The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors for treatment of type 2 diabetes is unknown. OBJECTIVE: To compare the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using network meta-analysis. DATA SOURCES: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, and published meta-analyses from inception through October 11, 2017...
April 17, 2018: JAMA
https://read.qxmd.com/read/29548001/hypertension-guidelines
#59
JOURNAL ARTICLE
Michel Burnier
No abstract text is available yet for this article.
March 14, 2018: European Heart Journal
https://read.qxmd.com/read/29523633/management-of-endocrine-disease-management-of-cushing-s-syndrome-during-pregnancy-solved-and-unsolved-questions
#60
REVIEW
Thierry Brue, Vincent Amodru, Frederic Castinetti
With fewer than 200 reported cases, Cushing's syndrome (CS) in pregnancy remains a diagnostic and therapeutic challenge. In normal pregnancies, misleading signs may be observed such as striae or hypokalemia, while plasma cortisol and urinary free cortisol may rise up to 2- to 3-fold. While the dexamethasone suppression test is difficult to use, reference values for salivary cortisol appear valid. Apart from gestational hypertension, differential diagnosis includes pheochromocytoma and primary aldosteronism...
June 2018: European Journal of Endocrinology
label_collection
label_collection
14587
3
4
2018-12-19 16:36:58
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.